Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389106 | 1.00 | KMT2A (0.55) | KMT2AMEN1ATMEPHX2EPHX1 | |
| SCHEMBL23389198 | 0.85 | EPHX2 (0.67) | EPHX2EPHX1POLB | |
| SCHEMBL23389197 | 0.85 | EPHX2 (0.67) | EPHX2EPHX1POLB | |
| SCHEMBL8232663 | 0.82 | SMN1; SMN2 (0.52) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL25153749 | 0.81 | EPHX2 (0.62) | EPHX2EPHX1POLB | |
| SCHEMBL15624940 | 0.81 | NPY5R (0.49) | KMT2AMEN1KDM4EALDH1A1POLB | |
| SCHEMBL20960357 | 0.81 | NPY5R (0.49) | KMT2AMEN1KDM4EALDH1A1POLB | |
| SCHEMBL23389238 | 0.80 | KMT2A (0.60) | KMT2AMEN1ATMEPHX2EPHX1 | |
| SCHEMBL23389237 | 0.80 | KMT2A (0.60) | KMT2AMEN1ATMEPHX2EPHX1 | |
| SCHEMBL23389085 | 0.79 | CA1 (0.49) | EPHX2EPHX1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | SHANGPHARMA INNOVATION INC. | 2025-08-21 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4061341-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885ATM 1316/4885 |
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885ATM 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.